Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2000 Apr;105(8):1045-7.
doi: 10.1172/JCI9872.

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

D Hanahan  1 , G Bergers, E Bergsland
Affiliations
Comment

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

D Hanahan et al. J Clin Invest. 2000 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The changing logic of chemotherapy: metronomic dosing at lower levels, in combination with other agents. The conventional logic of chemotherapy has been to treat cancers with closely spaced bolus infusions of drugs at or near the MTD, followed by substantial rest periods. The typical results were transitory improvements in tumor burden and life-span extension accompanied by disturbing side effects and eventual relapse. The new logic of chemotherapy involves dosing at constant intervals without rest periods (metronomic scheduling), the use of lower doses to minimize toxic side effects and eliminate the obligatory rest periods, and combination with other drugs targeting distinct aspects of a cancer’s functionality. The metronomic and combinatorial dosing strategies can kill tumor endothelial cells as well as overt cancer cells and, perhaps, other cellular constituents of a tumor, offering the prospect for genuine efficacy. The bullets refer to doses of chemotherapy, which can be large and episodic (upper scheme) or smaller and metronomic (lower); the bombs indicate other anti-cancer agents providing additive or synergistic benefits.
See this image and copyright information in PMC

Comment on

References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed
    1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364. - PubMed
    1. Folkman, J. 2000. Tumor angiogenesis. In Cancer medicine. Holland et al., editors. B.C. Decker Inc. Hamilton, Ontario, Canada. In press.
    1. Cancer trials: news and features. Angiogenesis inhibitors in clinical trials. http://cancertrials.nci.nih.gov/news/angio/table.html.
    1. Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–R24. - PMC - PubMed

MeSH terms